<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date>05/17/2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Dinesh</forename><surname>Khanna</surname></persName>
							<email>khannad@med.umich.edu</email>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><forename type="middle">A</forename><surname>Merkel</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Thomas</forename><surname>Krieg</surname></persName>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Franck-Olivier</forename><surname>Le Brun</surname></persName>
						</author>
						<author>
							<persName><roleName>BSc</roleName><forename type="first">Angelina</forename><surname>Marr</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kelly</forename><surname>Papadakis</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Janet</forename><surname>Pope</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marco</forename><surname>Matucci-Cerinic</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Daniel</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
						</author>
						<author>
							<persName><surname>Khanna</surname></persName>
						</author>
						<author>
							<persName><roleName>Merkel, Krieg</roleName><surname>Denton</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Le</forename><surname>Krieg</surname></persName>
						</author>
						<author>
							<persName><roleName>Marr</roleName><surname>Brun</surname></persName>
						</author>
						<author>
							<persName><roleName>Papadakis, Pope, Matucci-Cerinic</roleName><forename type="first">Furst</forename><surname>Marr</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">University of Michigan Scleroderma Program</orgName>
								<address>
									<addrLine>Ste 7C27, 300 N Ingalls St, SPC 5422</addrLine>
									<postCode>48109</postCode>
									<settlement>Ann Arbor</settlement>
									<region>MI</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Centre for Rheumatology and Connective Tissue Disease</orgName>
								<orgName type="institution">University of Michigan Scleroderma Program</orgName>
								<address>
									<settlement>Ann Arbor (Khanna)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Royal Free Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">Denton</orgName>
								<orgName type="institution" key="instit2">University of Pennsylvania</orgName>
								<address>
									<addrLine>Philadelphia (Merkel)</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country>Germany (Krieg</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Actelion Pharmaceuticals Ltd</orgName>
								<address>
									<addrLine>Switzerland (Le Brun, Papadakis)</addrLine>
									<settlement>Allschwil, Marr</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="institution">University of Western Ontario</orgName>
								<address>
									<settlement>London</settlement>
									<region>Ontario</region>
									<country>Canada (Pope</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Experimental and Clinical Medicine</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="institution" key="instit1">AOUC</orgName>
								<orgName type="institution" key="instit2">University of Florence</orgName>
								<address>
									<settlement>Florence</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Division of Rheumatology</orgName>
								<orgName type="institution" key="instit1">Italy (Matucci-Cerinic)</orgName>
								<orgName type="institution" key="instit2">UCLA</orgName>
								<address>
									<settlement>Los Angeles (Furst)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">Research Original Investigation Digital Ulcers in Patients With Systemic Sclerosis</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published">05/17/2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">CE0C545C49644AB95B1C9FA52FCD014A</idno>
					<idno type="DOI">10.1001/jama.2016.5258</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:47+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IMPORTANCE</head><p><s>Digital ulcers in patients with systemic sclerosis are associated with pain and poor quality of life.</s><s>Endothelin-1 promotes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blocker.</s></p><p><s>OBJECTIVE To evaluate the efficacy of macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis.</s></p><p><s>DESIGN, SETTING, AND PARTICIPANTS Two international, randomized, double-blind, placebo-controlled trials (DUAL-1, DUAL-2) were conducted between January 2012 and February 2014.</s><s>Participants were patients with systemic sclerosis and active digital ulcers at baseline.</s><s>Target enrollment for each study was 285 patients.</s></p><p><s>INTERVENTIONS Patients were randomized (1:1:1) to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily and stratified according to number of digital ulcers at baseline (Յ3 or &gt;3).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MAIN OUTCOMES AND MEASURES</head><p><s>The primary outcome for each trial was the cumulative number of new digital ulcers from baseline to week 16.</s><s>Treatment effect was expressed as the ratio between treatment groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>In DUAL-1, among 289 randomized patients (mean age 51.2 years; 85.8% women), 226 completed the study.</s><s>The adjusted mean number of new digital ulcers per patient over 16 weeks was 0.94 in the 3-mg macitentan group (n = 95) and 1.08 in the 10-mg macitentan group (n = 97) compared with 0.85 in the placebo group (n = 97) (absolute difference, 0.09 [95% CI, −0.37 to 0.54] for 3 mg of macitentan vs placebo and 0.23 [−0.27 to 0.72] for 10 mg of macitentan vs placebo).</s><s>Among 265 patients randomized in DUAL-2 (mean age 49.6 years; 81.9% women), 216 completed the study.</s><s>In DUAL-2, the adjusted mean number of new digital ulcers was 1.44 in the 3-mg macitentan group (n = 88) and 1.46 in the 10-mg macitentan group (n = 88) compared with 1.21 in the placebo group (n = 89) (absolute difference, 0.23 [95% CI, −0.35 to 0.82] for 3 mg of macitentan vs placebo and 0.25 [95% CI, −0.34 to 0.84] for 10 mg of macitentan vs placebo).</s><s>Adverse events more frequently associated with macitentan than with placebo were headache, peripheral edema, skin ulcer, anemia, upper respiratory tract infection, diarrhea, and nasopharyngitis.</s></p><p><s>CONCLUSIONS AND RELEVANCE Among patients with systemic sclerosis and active ischemic digital ulcers, treatment with macitentan did not reduce new digital ulcers over 16 weeks.</s><s>These results do not support the use of macitentan for the treatment of digital ulcers in this patient population.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S</head><p><s>ystemic sclerosis is a chronic multisystem autoimmune disease characterized by systemic vascular dysfunction and fibroblast dysregulation. <ref type="bibr">1</ref> Microvascular involvement contributes to the pathogenesis of the hallmark manifestations in systemic sclerosis, including pulmonary arterial hypertension, scleroderma renal crisis, Raynaud phenomenon, and digital ischemia. <ref type="bibr">1</ref></s><s>Digital ulcers are a clinical manifestation of digital ischemia that occur in 35% to 68% of patients with systemic sclerosis <ref type="bibr" target="#b7">[2]</ref><ref type="bibr" target="#b8">[3]</ref><ref type="bibr" target="#b9">[4]</ref><ref type="bibr" target="#b10">[5]</ref> and are associated with pain, disfigurement, poor quality of life, and disability. <ref type="bibr" target="#b7">2,</ref><ref type="bibr" target="#b11">6</ref></s><s>ystemic sclerosis-related vasculopathy is associated with the initiation and progression of systemic sclerosis and the development of digital ulcers. <ref type="bibr" target="#b12">7</ref></s><s>Endothelin-1 (ET-1) is a mediator of vascular hypertrophy, proliferation, inflammation, and fibrosis. <ref type="bibr" target="#b13">8</ref></s><s>T-1 is overexpressed in plasma in patients with systemic sclerosis, especially those with digital ulcers. <ref type="bibr" target="#b14">9</ref></s><s>ET receptors are upregulated in microvessels of skin in systemic sclerosis. <ref type="bibr">10</ref></s><s>The dual ET-receptor antagonist (ERA) bosentan significantly reduced the number of new digital ulcers in 2 randomized clinical trials (RCTs) of patients with systemic sclerosis with digital ulcers. <ref type="bibr" target="#b15">11,</ref><ref type="bibr" target="#b16">12</ref></s><s>acitentan is a novel dual ERA <ref type="bibr" target="#b17">13,</ref><ref type="bibr" target="#b18">14</ref> approved for long-term treatment of pulmonary arterial hypertension.</s></p><p><s>DUAL-1 and DUAL-2 are 2 RCTs that evaluated whether macitentan reduces the number of new digital ulcers and their associated disability in patients with systemic sclerosis and active ischemic digital ulcers.</s><s>DUAL-1 and DUAL-2 also evaluated the safety and tolerability of macitentan in this patient population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Design</head><p><s>DUAL-1 and DUAL-2 were phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group trials, designed to fulfill the regulatory requirement for providing substantial evidence of effectiveness.</s><s>Patients were enrolled in DUAL-1 at 70 centers in 17 countries from January 2012 to November 2013 and in DUAL-2 at 73 centers in 20 countries from February 2012 to February 2014.</s><s>Investigational sites were specific to each study; although, 6 countries were involved in both trials (eFigure in Supplement 1).</s><s>The trial protocols (Supplement 2 and Supplement 3) were approved by ethics committees at each center and the studies were performed in accordance with the principles of the Declaration of Helsinki and within the regulations of each country.</s><s>Written informed consent was obtained from all patients.</s><s>An independent data monitoring committee regularly reviewed unblinded efficacy and safety data, and an international liver safety board assessed all hepatic events (eTable 1 in Supplement 1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participant Selection</head><p><s>Inclusion criteria were age of at least 18 years; physician diagnosis of systemic sclerosis according to the 1980 American College of Rheumatology classification criteria <ref type="bibr" target="#b19">15</ref> with limited or diffuse cutaneous systemic sclerosis <ref type="bibr" target="#b20">16</ref> ; at least 1 visible, active ischemic digital ulcer located at or distal to the proximal interphalangeal joint that developed or worsened within 8 weeks prior to screening; and a history of additional active digital ulcers prior to screening (≥1 within 6 months or ≥2 within 12 months).</s><s>An active digital ulcer was defined as a finger lesion with visually discernible depth and a loss of continuity of epithelial coverage associated with pain not attributable to other etiologies.</s></p><p><s>Patients were excluded if they had digital ulcers not due to systemic sclerosis, or if they had comorbidities that could affect assessment of hand function.</s><s>Other exclusion criteria included any severe organ failure or life-threatening condition; tobacco use within 6 months before screening; treatment with phosphodiesterase type 5 inhibitors; treatment with prostanoids or ERAs within 3 months prior to screening or any investigational drug within 1 month prior to screening; and disease-modifying agents given for less than 3 months or at a nonstable dose for at least 1 month prior to screening.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Procedures</head><p><s>In each study, patients were randomly assigned (1:1:1) to receive 3 mg of macitentan, 10 mg of macitentan, or matching oral placebo once daily.</s><s>Treatment allocation was stratified by number of digital ulcers at randomization (≤3 and &gt;3) with a block size of 6.</s><s>Each patient was randomized via a centralized Interactive Response System (ICON) and received a unique randomization number.</s><s>The patients, investigators, and study sponsor remained blinded to treatment until database lock.</s></p><p><s>Patients were assessed at randomization and every 4 weeks up to week 16 (period 1).</s><s>Between week 16 and the end of the study they were assessed every 3 months (period 2) (eTable 2 in Supplement 1).</s><s>Patients continued double-blind treatment until the end of study, which occurred for all patients when the last patient completed the week-16 visit.</s><s>Within 7 days of the end of the study, patients completed the end of treatment visit.</s><s>Within 30 days of the end of the study, patients underwent their endof-study visit.</s><s>Patients who prematurely discontinued the study drug in period 1 or 2 completed the end of treatment visit within 7 days of the last administered dose.</s><s>These patients underwent follow-up every 3 months until the end of the study.</s><s>Adverse events (AEs) were monitored throughout the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome Measures</head><p><s>The primary efficacy end point was the cumulative number of new digital ulcers from baseline to week 16.</s><s>Digital ulcers that occurred and healed between visits were not recorded as new.</s><s>Complete healing was defined as complete epithelialization of the ischemic digital ulcer, regardless of residual pain.</s><s>Since there is low interrater reliability in assessing digital ulcers, <ref type="bibr" target="#b21">17</ref> each patient was assessed for digital ulcers by the same investigator throughout the study.</s><s>All investigators were trained to visualize and score the stages and types of digital ulcers in face-to-face meetings and were provided with a reference document to use during the study.</s></p><p><s>Other prespecified end points included the evaluation of hand function (assessed by the change between baseline and week 16 in Health Assessment Questionnaire-Disability Index [HAQ-DI] <ref type="bibr" target="#b22">18</ref> and Hand Disability in Systemic Sclerosis-Digital Ulcers [HDISS-DU] scores [eMethod in Supplement 1]); the evaluation of digital ulcer burden (assessed by the proportion of patients with or without multiple new digital ulcers at week 16 and by the change from baseline to week 16 in the total number of digital ulcers); the change from baseline to week 16 in the patient-and physician-reported global assessment of digital ulcer activity (severity of illness and global improvement; score range, 1-7); the proportion of patients with complete healing of all digital ulcers at week 16; the change from baseline to week 16 in overall hand pain related to digital ulcers (score range, 1-10); the change from baseline to week 16 in the Scleroderma Health Assessment Questionnaire visual analog scales (SHAQ-VAS; score range, 1-3) for overall global assessment of disease and for activity limitation due to digital ulcers and to Raynaud phenomenon <ref type="bibr" target="#b23">19</ref> ; and the evaluation of digital ulcer complications (assessed by the proportion of patients with digital ulcer complications at the end of treatment and the time from randomization to first digital ulcer complication up to the end of treatment).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analyses</head><p><s>For the primary end point, the null hypotheses were that the mean cumulative number of new digital ulcers per patient up to week 16 was the same between placebo vs 10-mg macitentan groups and between placebo vs 3-mg macitentan groups.</s><s>A sample size of 95 patients per treatment group (285 patients in total) was calculated by statistical simulations on the basis of a 2-sided comparison at the 5% significance level using an unstratified Pitman permutation test, 90% power, an overdispersion of 0.76, and an estimated 45% reduction in new digital ulcers at week 16 (based on an RCT comparing bosentan vs placebo, in which the mean number of new digital ulcers up to week 24 was 4.4 for placebo and 2.4 for bosentan). <ref type="bibr" target="#b16">12</ref></s><s>The use of a binomial-2 regression (NB-2) model <ref type="bibr" target="#b24">20</ref> adjusted for the number of digital ulcers at randomization (≤3 or &gt;3) was introduced before study start.</s><s>With the same sample size, it was estimated that a significant difference between the active and the placebo groups could be determined with greater than 97% power.</s><s>The treatment effect was expressed as the ratio of incidence rates of new digital ulcers over 16 weeks between each of the macitentan dose groups and the placebo group, and presented with corresponding 95% CIs.</s><s>The incidence rates were calculated as the cumulative number of new digital ulcers observed up to week 16 and were standardized to 16 weeks to account for different exposure times among patients.</s><s>The main imputation rules for missing values for the primary end point are explained in eTable 3 in Supplement 1.</s><s>This imputation method relies on the assumption of a constant rate of new digital ulcers occurring over time, as observed in previous studies <ref type="bibr" target="#b15">11,</ref><ref type="bibr" target="#b16">12</ref> and verified post hoc for these analyses.</s></p><p><s>A post hoc sensitivity analysis was performed using multiple imputation by fully conditional specification. <ref type="bibr">21</ref></s><s>Variables used for imputation were treatment group, number of digital ulcers at randomization, and the count of new digital ulcers at each visit up to week 16 (eTable 4 in Supplement 1).</s><s>Additional predefined sensitivity analyses of the primary end point were performed, as detailed in eTable 4 (Supplement 1).</s><s>A prespecified subgroup analysis evaluated the primary end point by number of digital ulcers at randomization (≤3 or &gt;3).</s></p><p><s>For other efficacy end points evaluating a change from baseline to week 16, treatment differences were analyzed using analy-sis of covariance.</s><s>Treatment differences for binary efficacy end points were expressed as odds ratios (ORs) calculated using logistic regression.</s><s>Treatment differences were adjusted for baseline values.</s><s>Missing data at week 16 were imputed using the last observation carried forward, and for HAQ-DI, the standard scoring was used. <ref type="bibr" target="#b23">19</ref></s><s>For time-to-event analyses, Kaplan-Meier estimates were calculated and proportional hazard models were used to compute hazard ratios (HRs) and 95% CIs.</s><s>All analyses were adjusted for the number of digital ulcers at randomization (≤3 or &gt;3).</s><s>Safety data were summarized descriptively.</s></p><p><s>The primary end point analysis was performed in the intention-to-treat population, whereas all other efficacy end point analyses were performed in the modified intention-totreat population (defined as all randomized patients who received ≥1 dose of study treatment and had ≥1 post-baseline primary efficacy assessment).</s><s>The safety analysis included all randomized patients who received at least 1 dose of study treatment.</s><s>The studies were planned to be reported separately.</s><s>All analyses were conducted using SAS version 9.3 (SAS Institute Inc), using a significance threshold of 5% with 2-sided P values.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Characteristics</head><p><s>In the DUAL-1 study, 289 patients were randomized to receive 3 mg of macitentan (n = 95), 10 mg of macitentan (n = 97), or placebo (n = 97) (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>In the DUAL-2 study, 265 patients were randomized to receive 3 mg of macitentan (n = 88), 10 mg of macitentan (n = 88), or placebo (n = 89) (Figure <ref type="figure">2</ref>).</s><s>In each study, groups were balanced with respect to patient demographics, disease characteristics, and concomitant medications (Table <ref type="table" target="#tab_1">1</ref>).</s><s>In DUAL-1, the number of digital ulcers at baseline ranged from 1 to 13 (mean, 3.4), and 201 patients (69.6%) presented with 3 or fewer digital ulcers.</s><s>In DUAL-2, the number of digital ulcers at baseline ranged from 1 to 18 (mean, 3.5), and 180 patients (67.9%) presented with 3 or fewer digital ulcers.</s><s>DUAL-2 was terminated prematurely based on recommendations by the independent data monitoring committee, which had overall responsibility for safeguarding the interests of the study participants by monitoring safety and efficacy data.</s><s>Although formal interim analyses were not predefined, the committee concluded, after reviewing unblinded data during a routine safety monitoring meeting (November 2013), that while risks of macitentan appeared modest, the possibility of any benefit was small and additional data were not expected to result in a positive primary outcome.</s><s>The committee recommended that DUAL-2 be halted and study treatment was discontinued in all patients (93.0% of planned patients had been enrolled and 74.7% of those underwent ≥16 weeks of treatment).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Development of New Digital Ulcers</head><p><s>The 2 trials did not achieve the primary end point of a reduction of cumulative number of new digital ulcers over 16 weeks (Table <ref type="table" target="#tab_3">2</ref>).</s><s>In DUAL-1, the adjusted mean numbers of new digital ulcers per patient over 16 weeks were 0.94 in the 3 mg of macitentan group, 1.08 in the 10 mg of macitentan group, and 0.85 in the placebo group, and observations were similar in DUAL-2 (adjusted mean number of new digital ulcers per patient over 16 weeks: 1.44 in the 3 mg of macitentan group, 1.46 in the 10 mg of macitentan group, and 1.21 in the placebo group).</s><s>In DUAL-1, the absolute difference for the cumulative number of new digital ulcers from baseline to week 16 was 0.09 (95% CI, −0.37 to 0.54) and the rate ratio was 1.10 (95% CI, 0.66 to 1.83) (P = .71)</s><s>for 3 mg of macitentan vs placebo; for 10 mg of macitentan vs placebo, the absolute difference was 0.23 (95% CI, −0.27 to 0.72) and the rate ratio was 1.27 (95% CI, 0.76 to 2.11) (P = .36).</s></p><p><s>In DUAL-2, the absolute difference for the cumulative number of new digital ulcers from baseline to week 16 was 0.23 (95% CI, −0.35 to 0.82) and the rate ratio was 1.19 (95% CI, 0.77 to 1.86) (P = .43)</s><s>for 3 mg of macitentan vs placebo; for 10 mg of macitentan vs placebo, the absolute difference was 0.25 (95% CI, −0.34 to 0.84) and the rate ratio was 1.21 (95% CI, 0.77 to 1.89) (P = .41).</s><s>These results were confirmed using multiple imputation and other prespecified sensitivity analyses (eTable 4 in Supplement 1).</s><s>The amount of missing data for the primary end point is shown in eTable 5 (Supplement 1; patients with ≥1 missing assessment: DUAL-1, 23.5% [n = 68]; DUAL-2, 24.9% [n = 66]).</s><s>The absence of a treatment effect was also observed in the subgroups of patients with 3 or fewer digital ulcers at baseline vs greater than 3 (Table <ref type="table" target="#tab_3">2</ref>).</s><s>In DUAL-1, 64.1% (59) of patients in the 3 mg of macitentan group, 63.0% (58) of patients in the 10 mg of macitentan group, and 67.0%</s><s>(63) of patients in the placebo group had no new digital ulcers by week 16.</s><s>In DUAL-2, 56.0% (47) of those in the 3 mg of macitentan group, 54.8% (46) of patients in the 10 mg of macitentan group, and 59.8% (52) of patients in the placebo group had no new digital ulcers by week 16 (Table <ref type="table" target="#tab_4">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hand Function, Digital Ulcers Burden, and Time to Digital Ulcers Complications</head><p><s>There were no treatment effects with either dose of macitentan vs placebo in either trial with respect to other efficacy end points, including hand function, digital ulcer burden, patient-and physician-reported outcomes, complete healing of digital ulcers, and overall hand pain related to digital ulcers and  SHAQ (Table <ref type="table" target="#tab_4">3</ref>).</s><s>In all groups, patients showed reduction from baseline to week 16 in total number of digital ulcers, severity of disease (patient-and physician-rated), pain, and interference with daily activity.</s><s>There was little change in hand function (Table <ref type="table" target="#tab_4">3</ref>).</s><s>In both trials, no differences between groups were observed in time to first digital ulcer complications (Figure <ref type="figure" target="#fig_4">3</ref>).</s><s>Digital ulcer complications were observed in 17.6% of patients in DUAL-1 and in 21.2% of patients in DUAL-2 (eTable 6 in Supplement 1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety and Tolerability</head><p><s>In both trials, patients were exposed to treatment on average for 40 weeks (eTable 7 in Supplement 1).</s><s>In this period, the frequency of patients in DUAL-1 with at least 1 AE was 71.3% among those in the In DUAL-1, data were missing for 1 patient in the placebo group; in DUAL-2, data were missing for 2 in the placebo group and 2 in the macitentan 3-mg group.</s></p><p><s>c</s></p><p><s>In DUAL-2, data were missing for 1 patient in the macitentan 3-mg group.</s></p><note type="other">d</note><p><s>In DUAL-1, data were missing for 1 patient in the placebo group; in DUAL-2, data were missing for 3 in the macitentan 3-mg group and 1 in the macitentan 10-mg group.</s></p><p><s>e</s></p><p><s>In DUAL-1, data were missing for 2 patients in both the placebo and macitentan 10-mg groups; in DUAL-2, data were missing for 1 in both the placebo and macitentan 10-mg groups.</s></p><p><s>f</s></p><p><s>In DUAL-1, data were missing for 6 patients in the placebo group, 4 in the macitentan 3-mg group, and 8 in the macitentan 10-mg group; in DUAL-2, data were missing for 4 in the placebo group, 5 in the macitentan 3-mg group, and 2 in the macitentan 10-mg group.</s></p><p><s>g Higher score indicates a worse patient-or physician-reported score.</s><s>Score ranges: HAQ-DI (0-3), HDISS-DU (0-7), overall hand pain related to digital ulcers (1-10), and SHAQ-VAS (0-3).</s></p><p><s>h Score is based on a 7-point Likert scale (range: 1, very much worse; 4, no change; 7, very much improved).</s></p><p><s>i</s></p><p><s>In DUAL-1, data were missing for 1 patient in the macitentan 3-mg group.</s></p><note type="other">j</note><p><s>In DUAL-1, data were missing for 6 patients in the placebo group, 4 in the macitentan 3-mg group, and 8 in the macitentan 10-mg group; in DUAL-2, data were missing for 5 in the placebo group, 7 in the macitentan 3-mg group, and 4 in the macitentan 10-mg group.</s></p><p><s>k</s></p><p><s>In DUAL-2, data were missing for 1 patient in the placebo group, 2 in the macitentan 3-mg group, and 2 in the macitentan 10-mg group.</s><s>The global improvement scale is only measured at follow-up visits and the analysis for this outcome is based on the between-group (adjusted for baseline digital ulcers</s></p><p><s>Ն3 vs &lt;3) mean difference at week 16.</s></p><p><s>and 13.4% in the placebo group, and in DUAL-2, 11.4% in the 3 mg of macitentan group, 24.1% for 10 mg of macitentan, and 14.6% in the placebo group, with infections being the most common.</s></p><p><s>There was 1 death due to cardiac arrest in DUAL-1 in a patient receiving 10 mg of macitentan.</s><s>There were 2 deaths (1 due to unspecified natural causes and 1 due to cardiac failure) in DUAL-2.</s><s>Both patients were in the 10 mg of macitentan group.</s><s>All deaths were considered unrelated to study treatment.</s><s>There were no differences in alanine aminotransferase, aspartate aminotransferase, bilirubin, or hemoglobin between study groups (eTable 7 in Supplement 1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In 2 randomized, placebo-controlled trials of patients with systemic sclerosis and active ischemic digital ulcers at baseline, macitentan did not reduce the cumulative number of new digital ulcers over 16 weeks compared with placebo.</s><s>Re-gardless of treatment, patients had few new digital ulcers, and their overall digital ulcer condition remained stable over 16 weeks.</s><s>Macitentan was well tolerated, with a safety profile similar to that observed in patients with pulmonary arterial hypertension <ref type="bibr" target="#b25">22</ref> and idiopathic pulmonary fibrosis. <ref type="bibr" target="#b26">23</ref></s><s>ew therapies are available for digital ulcers in patients with systemic sclerosis.</s><s>The EUSTAR 2009 treatment recommendations in systemic sclerosis for managing digital ulcers endorse using intravenous iloprost and bosentan, <ref type="bibr" target="#b27">24</ref> and evidence supporting the use of PDE-5 inhibitors is recently available. <ref type="bibr" target="#b28">25</ref></s><s>Bosentan is the only treatment indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease, following 2 randomized clinical trials, RAPIDS-1 and RAPIDS-2. <ref type="bibr" target="#b15">11,</ref><ref type="bibr" target="#b16">12</ref></s><s>Because bosentan is not approved in all of the countries where the DUAL studies were conducted, DUAL-1 and DUAL-2 did not compare macitentan to bosentan.</s><s>Instead, the trials were placebo-controlled with safeguards in place in case of progression of digital ulcer severity.</s><s>The choice of bosentan as an active  comparator would have limited the scope of the studies.</s><s>Current European guidelines state that bosentan should be considered in diffuse systemic sclerosis with multiple digital ulcers after failure of calcium antagonists and prostanoids. <ref type="bibr" target="#b27">24</ref></s><s>UAL-1 and DUAL-2 were designed to fulfill the regulatory requirements for demonstrating the effectiveness of macitentan vs placebo.</s></p><p><s>Based on results of the RAPIDS trials, the inclusion criteria of DUAL-1 and DUAL-2 were designed to enroll patients with high likelihood of developing new digital ulcers.</s><s>The number of active digital ulcers at baseline ranged from 1 to 18 in the 2 studies.</s><s>Although most participants (69.6%) had 3 or fewer digital ulcers at baseline, the average number of digital ulcers was 3.5, thus the study population consisted of systemic sclerosis patients with active digital ulcers.</s></p><p><s>The average number of new digital ulcers over 16 weeks was low, ranging from 0.85 to 1.46 ulcers across the treatment groups in both studies.</s><s>Approximately 60% of patients did not develop new digital ulcers.</s><s>Even among patients with more than 3 active digital ulcers at baseline, the average number of new digital ulcers over 16 weeks ranged from 1.16 to 2.66 in the 3 treatment groups.</s><s>In RAPIDS-1, <ref type="bibr" target="#b15">11</ref> patients treated with placebo with 1 to 3 active digital ulcers at baseline developed, a mean (SD) of 2.2 (2.0) new digital ulcers over 16 weeks, and those with more than 3 active digital ulcers at baseline developed 5.1 (3.9) new ulcers.</s><s>Overall, 42% of the patients in RAPIDS-1 had more than 3 new digital ulcers over 16 weeks. <ref type="bibr" target="#b15">11</ref></s><s>esults were similar in RAPIDS-2. <ref type="bibr" target="#b16">12</ref></s><s>DUAL-1 and DUAL-2 were designed with the expectation that patients receiving placebo would develop more digital ulcers.</s></p><p><s>Patients enrolled in DUAL-1 and DUAL-2 had similar demographics and disease characteristics as patients enrolled in prior systemic sclerosis digital ulcer trials.</s><s>The low number of new digital ulcers observed suggests that the epidemiology of digital ulcers in systemic sclerosis may be changing and reflect earlier diagnosis, better care, and greater availability of treatments.</s><s>A similarly low incidence of new digital ulcers in patients with systemic sclerosis was also observed in a recent study. <ref type="bibr" target="#b30">26</ref></s><s>Standard management of digital ulcers has improved in recent years with the widespread use of bosentan, PDE-5 inhibitors, and prostacyclin and its analogs. <ref type="bibr" target="#b31">27,</ref><ref type="bibr" target="#b32">28</ref></s><s>It is possible that patients with more severe active ulcers were treated with these medications and not recruited into the DUAL trials or that the studies enrolled a population with refractory digital ulcers that did not respond well to standard treatments.</s><s>Enrolled patients may have exhausted other treatment options.</s></p><p><s>30]<ref type="bibr" target="#b36">[31]</ref> However, the specific role of ET-1 in the pathogenesis of digital vasculopathy and the development of digital ulcers in systemic sclerosis is incompletely understood.</s><s>Although bosentan and macitentan both block the ET A and ET B receptors, a reduction in the formation of new digital ulcers has only been observed with bosentan. <ref type="bibr" target="#b15">11,</ref><ref type="bibr" target="#b16">12</ref></s><s>Macitentan is a more potent ERA than bosentan on ET receptors in vitro and on biomarkers (eg, plasma ET-1) and other measures (eg, blood pressure and cardiac remodeling) in in vivo models of pulmonary hypertension. <ref type="bibr" target="#b37">32</ref></s><s>It is unclear why this relative higher potency of macitentan did not result in an effect on digital ulcers.</s><s>Further research is necessary to delineate mechanisms of vascular involvement in systemic sclerosis as it relates to digital ulcers.</s><s>The etiology of digital ulceration in systemic sclerosis is multifactorial, involving ischemic, inflammatory, and mechanical mechanisms, all of which influence clinical outcomes of digital ulcers, including repetitive microtrauma, thinning, dry skin, and underlying calcinosis.</s></p><p><s>Limitations of the DUAL-1 and DUAL-2 studies include the lack of a clear classification system of digital ulcers that considers digital ulcer morphology and the different ulcer features, including presence of underlying calcinosis, size, bedding, perilesional skin, and borders, which potentially affect digital ulcer assessment and counts. <ref type="bibr" target="#b11">6,</ref><ref type="bibr" target="#b12">7</ref></s><s>The DUAL studies involved 73 centers in 20 countries.</s><s>Although efforts were made to standardize the definition and the reporting of new active digital ulcers, some variability across the study sites in measuring new digital ulcers was likely, and the absence of interrater reliability data to quantify this is a limitation.</s><s>In addition, 23.5% of participants in DUAL-1 and 24.9% of those in DUAL-2 were missing primary outcome data at 16-week followup.</s><s>However, the primary end point considers the cumulative number of new digital ulcers up to week 16, and the consistency of sensitivity analyses suggests that missing data did not significantly affect statistical inference.</s><s>Differences in physician attitudes and standard practices, <ref type="bibr" target="#b21">17</ref> and the lower than expected number of new digital ulcers after 16 weeks may have ultimately influenced the ability to demonstrate any treatment effect in the DUAL trials.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Among patients with systemic sclerosis and active ischemic digital ulcers, treatment with macitentan did not reduce the number of new digital ulcers over 16 weeks.</s><s>These results do not support the use of macitentan for the treatment of digital ulcers in this patient population.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Flow of Study Participants for DUAL-1</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>Abbreviations: HAQ-DI, Health Assessment Questionnaire-Disability Index; HDISS-DU, Hand Disability in Systemic Sclerosis-Digital Ulcers; SHAQ-VAS, Scleroderma Health Assessment Questionnaire visual analog scale.</s><s>a Treatment differences are presented as adjusted mean differences for continuous outcomes and odds ratios for binary responses.</s><s>All analyses are adjusted for the baseline score of the same variable (except the global improvement scale which has no baseline value) and the stratification factor (digital ulcers Ն3 vs digital ulcers &lt;3).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3.</s><s>Time to First Digital Ulcer Complication Up to End of Treatment in DUAL-1 and DUAL-2</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Figure 2. Flow of Study Participants for DUAL-2 Patient and Disease Characteristics at Baseline</s></p></div></figDesc><table><row><cell>those in the 3 mg of macitentan group, 85.1% for 10 mg of maci-</cell></row><row><cell>tentan, and 78.7% for the placebo group (eTable 7 in Supplement</cell></row><row><cell>1). The most frequently reported AEs (incidence rate, 10% and</cell></row><row><cell>&gt;3% difference between placebo and either macitentan group)</cell></row><row><cell>in each trial were headache, peripheral edema, skin ulcer, ane-</cell></row><row><cell>mia, upper respiratory tract infection, diarrhea, and nasophar-</cell></row><row><cell>yngitis. AEs leading to premature discontinuation occurred in</cell></row><row><cell>13.8% of patients in the 3 mg of macitentan group, 14.4% for 10</cell></row><row><cell>mg of macitentan, and 10.3% of patients in the placebo group</cell></row><row><cell>in DUAL-1, and in DUAL-2, AEs leading to premature discontinu-</cell></row><row><cell>ation occurred in 9.2% of patients in the 3 mg of macitentan</cell></row><row><cell>0% among</cell></row></table><note><p><s>3 mg of macitentan group, 76.3% for 10 mg of macitentan , and 73.2% for the placebo group, and in DUAL-2, the frequency of patients with at least 1 AE was 83.group, 17.2% for 10 mg of macitentan, and 14.6% of patients in the placebo group.</s><s>Skin ulcer, infected skin ulcer, and increased alanine aminotransferase/aspartate aminotransferase were the most frequently reported AEs leading to treatment discontinuation.</s><s>Incidences of serious AEs in DUAL-1 were 18.1% in the 3 mg of macitentan group, 14.4% for 10 mg of macitentan, jama.com</s><s>(Reprinted) JAMA May 10, 2016 Volume 315, Number 18</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient and Disease Characteristics at Baseline (continued)</s></p></div></figDesc><table><row><cell>DUAL-1</cell></row><row><cell>Characteristics</cell></row></table><note><p><s>a Defined by the investigator, another member of the medical staff, or the patient.</s><s>b</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>were missing for 1 patient in the placebo group, 2 in the macitentan 3-mg group, and 3 in the macitentan 10-mg group.</s><s>Effect of Macitentan on the Incidence of Digital Ulcers to Week 16 in DUAL-1 and DUAL-2</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>10-mg Macitentan vs Placebo</cell><cell>RR (95% CI) P Value</cell><cell></cell><cell></cell><cell>1.27 .36</cell><cell>(0.76 to 2.11)</cell><cell></cell><cell>1.40 .29</cell><cell>(0.75 to 2.60)</cell><cell></cell><cell>1.03 .95</cell><cell>(0.43 to 2.46)</cell><cell></cell><cell></cell><cell>1.21 .41</cell><cell>(0.77 to 1.89)</cell><cell></cell><cell>1.14 .69</cell><cell>(0.60 to 2.17)</cell><cell>1.32 .37</cell><cell>(0.73 to 2.40)</cell></row><row><cell></cell><cell>Treatment Effect</cell><cell>3-mg Macitentan vs Placebo</cell><cell>RR (95% CI) P Value</cell><cell></cell><cell></cell><cell>1.10 .71</cell><cell>(0.66 to 1.83)</cell><cell></cell><cell>1.09 .80</cell><cell>(0.58 to 2.05)</cell><cell></cell><cell>1.14 .77</cell><cell>(0.48 to 2.67)</cell><cell></cell><cell></cell><cell>1.19 .43</cell><cell>(0.77 to 1.86)</cell><cell></cell><cell>1.02 .94</cell><cell>(0.54 to 1.95)</cell><cell>1.48 .19</cell><cell>(0.83 to 2.67)</cell></row><row><cell>Absolute Difference (95% CI),</cell><cell>Macitentan vs Placebo</cell><cell></cell><cell>3-mg Macitentan 10-mg Macitentan</cell><cell></cell><cell></cell><cell>0.09 0.23</cell><cell>(−0.37 to 0.54) (−0.27 to 0.72)</cell><cell></cell><cell>0.06 0.25</cell><cell>(−0.37 to 0.48) (−0.22 to 0.73)</cell><cell></cell><cell>0.16 0.04</cell><cell>(−0.91 to 1.22) (−0.99 to 1.06)</cell><cell></cell><cell></cell><cell>0.23 0.25</cell><cell>(−0.35 to 0.82) (−0.34 to 0.84)</cell><cell></cell><cell>0.02 0.11</cell><cell>(−0.49 to 0.53) (−0.43 to 0.65)</cell><cell>0.87 0.57</cell><cell>(−0.44 to 2.17) (−0.68 to 1.82)</cell></row><row><cell>Incidence to Week 16,</cell><cell>Adjusted Mean (95% CI) a</cell><cell></cell><cell>3-mg Macitentan 10-mg Macitentan Placebo</cell><cell></cell><cell>95 97 97</cell><cell>0.94 1.08 0.85</cell><cell>(0.65 to 1.35) (0.75 to 1.56) (0.59 to 1.23)</cell><cell>67 67 67</cell><cell>0.69 0.89 0.64</cell><cell>(0.45 to 1.08) (0.58 to 1.37) (0.41 to 1.00)</cell><cell>28 30 30</cell><cell>1.32 1.20 1.16</cell><cell>(0.72 to 2.43) (0.64 to 2.25) (0.64 to 2.13)</cell><cell></cell><cell>88 88 89</cell><cell>1.44 1.46 1.21</cell><cell>(1.06 to 1.96) (1.07 to 1.99) (0.87 to 1.67)</cell><cell>60 60 60</cell><cell>0.80 0.89 0.78</cell><cell>(0.51 to 1.26) (0.57 to 1.40) (0.50 to 1.24)</cell><cell>28 28 29</cell><cell>2.66 2.36 1.79</cell><cell>(1.79 to 3.95) (1.56 to 3.58) (1.16 to 2.76)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Patients</cell><cell>DUAL-1</cell><cell>Overall, No. of patients b</cell><cell cols="2">New digital ulcers per patient, mean (95% CI) c</cell><cell>≤3 Digital ulcers at baseline, No. of patients b</cell><cell cols="2">New digital ulcers per patient, mean (95% CI) c</cell><cell>&gt;3 Digital ulcers at baseline, No. of patients b</cell><cell cols="2">New digital ulcers per patient, mean (95% CI) c</cell><cell>DUAL-2</cell><cell>Overall, No. of patients b</cell><cell cols="2">New digital ulcers per patient, mean (95% CI) c</cell><cell>≤3 Digital ulcers at baseline, No. of patients b</cell><cell cols="2">New digital ulcers per patient, mean (95% CI) c</cell><cell>&gt;3 Digital ulcers at baseline, No. of patients b</cell><cell>New digital ulcers per patient, mean (95% CI) c</cell><cell>Abbreviation: RR, rate ratio.</cell></row></table><note><p><s>l In DUAL-2, data m Platelet aggregation inhibitors used were beraprost, clopidogrel, acetylsalicylic acid, asasantin, cilostazol, and dipyridamole.n</s><s>Disease-modifying antirheumatic drugs used were aminoquinolines, azathioprine, cyclophosphamide, methotrexate, d-penicillamine, rituximab, and other selective immunosuppressants.Digital Ulcers in Patients With Systemic Sclerosis Original Investigation Research jama.com (Reprinted) JAMA May 10, 2016 Volume 315, Number 18 1981 a Digital ulcer incidence was estimated from a negative binomial model.b</s><s>For the number of patients with imputed data for each visit over 16 weeks, see eTable 5 (Supplement 1).cAnalyses were adjusted for the number of digital ulcers at randomization (Յ3 or &gt;3).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Effect of Macitentan at Week 16 on Selected Outcomes in DUAL-1 and DUAL-2</s></p></div></figDesc><table><row><cell>Treatment Effect a</cell></row><row><cell>Placebo</cell></row><row><cell>10 mg Macitentan</cell></row><row><cell>3-mg Macitentan</cell></row><row><cell>Secondary Outcomes</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Effect of Macitentan at Week 16 on Selected Outcomes in DUAL-1 and DUAL-2 (continued)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>P Value</cell><cell>.40</cell><cell></cell><cell>.58</cell><cell></cell><cell>.76</cell><cell></cell><cell>.97</cell><cell></cell><cell>.75</cell><cell></cell><cell></cell><cell>.41</cell></row><row><cell></cell><cell>10-mg Macitentan</cell><cell>vs Placebo</cell><cell>−0.2</cell><cell>(−0.6 to 0.2)</cell><cell>−0.1</cell><cell>(−0.5 to 0.3)</cell><cell>−0.1</cell><cell>(−0.4 to 0.3)</cell><cell>0</cell><cell>(−0.4 to 0.4)</cell><cell>0.90</cell><cell>(0.49 to 1.69)</cell><cell></cell><cell>−0.3</cell><cell>(−1.0 to 0.4)</cell></row><row><cell></cell><cell></cell><cell>P Value</cell><cell>.24</cell><cell></cell><cell>.31</cell><cell></cell><cell>.42</cell><cell></cell><cell>.94</cell><cell></cell><cell>.52</cell><cell></cell><cell></cell><cell>.16</cell></row><row><cell>Treatment Effect a</cell><cell>3-mg Macitentan</cell><cell>vs Placebo</cell><cell>−0.2</cell><cell>(−0.6 to 0.2)</cell><cell>0.2</cell><cell>(−0.2 to 0.6)</cell><cell>−0.2</cell><cell>(−0.5 to 0.2)</cell><cell>0</cell><cell>(−0.4 to 0.4)</cell><cell>0.81</cell><cell>(0.43 to 1.52)</cell><cell></cell><cell>−0.5</cell><cell>(−1.2 to 0.2)</cell></row><row><cell></cell><cell></cell><cell>Week-16 Value</cell><cell>−0.9</cell><cell>(−1.1 to −0.6)</cell><cell>4.9</cell><cell>(4.6 to 5.2)</cell><cell>−1.0</cell><cell>(−1.3 to −0.7)</cell><cell>5.1</cell><cell>(4.8 to 5.4)</cell><cell>35 (40.2)</cell><cell></cell><cell></cell><cell>−1.8</cell><cell>(−2.3 to −1.2)</cell></row><row><cell>Placebo</cell><cell>No.</cell><cell>(Imputed) b</cell><cell>86 (15)</cell><cell></cell><cell>86 (15)</cell><cell></cell><cell>87 (17)</cell><cell></cell><cell>87 (17)</cell><cell></cell><cell>87 (16)</cell><cell></cell><cell></cell><cell>86 (15)</cell></row><row><cell>10 mg Macitentan</cell><cell>No.</cell><cell>(Imputed) b Week-16 Value</cell><cell>82 (17) −0.9</cell><cell>(−1.2 to −0.6)</cell><cell>82 (17) 4.8</cell><cell>(4.5 to 5.1)</cell><cell>83 (18) −1.0</cell><cell>(−1.2 to −0.7)</cell><cell>83 (18) 5.1</cell><cell>(4.8 to 5.4)</cell><cell>84 (18) 32 (38.1)</cell><cell></cell><cell></cell><cell>82 (17) −1.7</cell><cell>(−2.2 to −1.2)</cell></row><row><cell></cell><cell></cell><cell>Week-16 Value</cell><cell>−0.9</cell><cell>(−1.3 to −0.6)</cell><cell>5.1</cell><cell>(4.8 to 5.4)</cell><cell>−1.2</cell><cell>(−1.5 to −0.9)</cell><cell>5.1</cell><cell>(4.9 to 5.4)</cell><cell>30 (35.7)</cell><cell></cell><cell></cell><cell>−1.9</cell><cell>(−2.5 to −1.3)</cell></row><row><cell>3-mg Macitentan</cell><cell>No.</cell><cell>(Imputed) b</cell><cell>82 (13)</cell><cell></cell><cell>82 (13)</cell><cell></cell><cell>83 (13)</cell><cell></cell><cell>83 (13)</cell><cell></cell><cell>84 (14)</cell><cell></cell><cell></cell><cell>83 (15)</cell></row><row><cell></cell><cell></cell><cell>Secondary Outcomes</cell><cell>Patient-reported global assessment</cell><cell>of digital ulcer severity, mean change (95% CI) d</cell><cell cols="2">Global improvement, mean (95% CI) d,e</cell><cell>Physician-reported global assessment</cell><cell>of digital ulcer severity, mean change (95% CI) d</cell><cell cols="2">Global improvement, mean (95% CI) d,e</cell><cell>Patients with complete healing</cell><cell>of all digital ulcers at week 16,</cell><cell>No. (%)</cell><cell cols="2">Overall hand pain related to digital ulcers, mean change (95% CI) c</cell><cell>SHAQ-VAS c</cell><cell>Overall global assessment of disease,</cell><cell>mean change (95% CI)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">JAMA May 10, 2016 Volume 315, Number 18 (Reprinted) jama.com Copyright 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</s><s>Dr Khanna reports receipt of grants from EMD Serono, Bristol-Myers Squibb, Bayer, InterMune, the National Institutes of Health (NIH)/the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the Scleroderma Foundation, and the Pulmonary Hypertension Association; and consulting fees from Actelion, Astra-Zeneca, Bayer, Biogen Idec, Bristol-Myers Squibb, Cytori, EMD Serono, Genentech/Roche, GlaxoSmithKline, and Sanofi-Aventis/Genzyme. Mr Le Brun, Ms Marr, and Dr Papadakis report being employees of and holding stocks in Actelion Pharmaceuticals Ltd. Dr Denton reports having acted as a consultant for and receiving speaker fees from Actelion, GlaxoSmithKline, Bayer, Inventiva, and Takeda; and receipt of research grant support from Actelion, CSL Behring, GlaxoSmithKline, and Novartis.</s><s>Dr Pope reports having been a consultant for Actelion and Bayer.</s><s>Dr Merkel reports receipt of consulting fees from Actelion, Alexion, ChemoCentryx, Genentech/Roche, and Sanofi; research funding from Actelion, Bristol-Myers Squibb, Celgene, ChemoCentryx, and GlaxoSmithKline; and receipt of research grants from NIH, the US Food and Drug Administration, and the American College of Rheumatology and Vasculitis Foundation.</s><s>Dr Krieg reports receipt of research grants and speakers fees from Actelion.</s><s>Dr Matucci-Cerinic reports receipt of grant/research support and/or speaker's bureau attendance from Actelion, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and Abbott.</s><s>Dr Furst reports receipt of grant/research support from AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, NIH, Novartis, Pfizer, Roche/ Genentech, UCB; consulting fees from AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Janssen, Gilead, GlaxoSmithKline, NIH, Novartis, Pfizer, Roche/Genentech, UCB; and speaker's fees (CME only) from AbbVie, Actelion, and UCB.</s></p><p><s>Funding/Support: DUAL-1 and DUAL-2 were funded by Actelion Pharmaceuticals Ltd.</s></p><p><s>Role of the Funder/Sponsor: Actelion Pharmaceuticals Ltd was involved in the design and conduct of the study; oversaw the collection, management, and statistical analysis of the data; and contributed to the interpretation of the data and the preparation, review, and approval of the manuscript.</s><s>The final decision on manuscript submission was made by the authors; the sponsor did not have the ability to veto publication of study results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Collaborators</head><p><s>The DUAL-1 and DUAL-2 principal investigators who contributed to the recruitment of patients in the studies are listed by country.</s><s>Additional Contributions: The authors express their gratitude to all investigators, study staff, and patients who participated in these studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DUAL</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Mexico</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Clinica Diagnostico y Tratamiento de las Enfermedades Reumaticas</title>
		<author>
			<persName><forename type="first">Gabriel</forename><surname>Medrano-Ramirez</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<imprint>
			<pubPlace>Mexico DF</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Kristine (Pek Ling) Ng, MD, North Shore Hospital</title>
		<author>
			<persName><forename type="first">Jorge</forename><surname>Morales-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Morale</forename><surname>Vargas Centro De Investigacion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Leon; Cesar Francisco</forename><surname>Pacheco-Tena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Investigación Y Biomedicina De Chihuahua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chihuahua; Adriana</forename><surname>Sanchez-Ortiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Unidad</forename><surname>De Artritis Y Reumatismo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Guadalajara</forename><surname>Netherlands: Madelon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vonk</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>St Radboud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Simon Stebbings, MBBS, Dunedin Hospital</title>
		<imprint>
			<publisher>Kamal Solanki</publisher>
		</imprint>
		<respStmt>
			<orgName>MD, Reumatika-Centrum Reumatologii NZOZ, Warszaw; Marek Brzosko, MD, Department of Rheumatology and Internal Diseases, Pomeranian Medical University</orgName>
		</respStmt>
	</monogr>
	<note>Anna Zubrzycka-Sienkiewicz</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Jacek</surname></persName>
		</author>
		<author>
			<persName><surname>Szepietowski</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Nr 1 Wrocław</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hrycaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Prywatna</forename><surname>Praktyka Lekarska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Poznań</forename><surname>Portugal: Ivone Fernandes Santos Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Santo António</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Centro</forename><surname>Hospitalar Do Porto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Porto; Lelita</forename><surname>Da Conceiçao Dos Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Hospitais</forename><surname>Da Universidade De Coimbra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Coimbra; Paulo Jorge Clemente</forename><surname>Coelho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Instituto</forename><surname>Português De Reumatologia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lisboa</forename><surname>Rico</surname></persName>
		</author>
		<title level="m">City Clinical Hospital #5</title>
				<meeting><address><addrLine>MD, University of Puerto Rico, San Juan. Russian Federation; Tatiana Chernykh, MD, Voronezh State Medical Academy, Vorobnezh; Elena Grunina, MD; Nizhniy Novgorod</addrLine></address></meeting>
		<imprint>
			<publisher>Grissel Rios</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Syeve</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Biko Hospital</surname></persName>
		</author>
		<author>
			<persName><surname>Pretoria; Asgar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Kalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Groote</forename><surname>Schuur Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cape</forename><surname>Town</surname></persName>
		</author>
		<author>
			<persName><surname>Turkey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vinnytsia Regional Clinical Hospital</title>
		<imprint>
			<publisher>Andriy</publisher>
		</imprint>
		<respStmt>
			<orgName>Marina Stanislav, MD, Scientific Research Institute of Rheumatology, Moscow. South Africa: Mahmood Ally, ; Ahmet Merih Birlik, MD, Dokuz Eylul Universitesi, Izmir. Ukraine: Volodymyr Kovalenko ; Crimean Republican Institution, University Clinic, Symferopol; Sergiy Shevchuk, MD, National Medical University, Vinnytsya; Mykola Stanislavchuk, MD</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<author>
			<persName><forename type="first">Cristopher</forename><forename type="middle">P</forename><surname>Liverpool</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Denton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">The</forename><surname>Royal Free</surname></persName>
		</author>
		<author>
			<persName><forename type="first">London; Ariane</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Herrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Salford</forename><surname>Royal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Salford; Jill Belch, MD</title>
				<meeting><address><addrLine>Redwood City, CA</addrLine></address></meeting>
		<imprint/>
		<respStmt>
			<orgName>United Kingdom: Marina Anderson, MD, University Hospital Aintree ; MD, Stanford University School of Medicine</orgName>
		</respStmt>
	</monogr>
	<note>NHS Foundation Trust</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Review: evidence that systemic sclerosis is a vascular disease</title>
		<author>
			<persName><forename type="first">Mary</forename><forename type="middle">Ellen</forename><surname>Csuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Matucci-Cerinic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kahaleh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wigley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1953" to="1962" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Functional impairment of systemic scleroderma patients with digital ulcerations</title>
		<author>
			<persName><forename type="first">L</forename><surname>Guillevin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hunsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="71" to="80" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Clinical risk assessment of organ manifestations in systemic sclerosis</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tyndall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Czirják</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="754" to="763" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Digital ulcers: overt vascular disease in systemic sclerosis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Steen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Pope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Matucci-Cerinic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="19" to="24" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Natural history of ischemic digital ulcers in systemic sclerosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Hachulla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Clerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Launay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2423" to="2430" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Digital ulcers in scleroderma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Amanzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Braschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fiori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1374" to="1382" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Digital ulcers and outcomes assessment in scleroderma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Matucci-Cerinic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Seibold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="46" to="47" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Distler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Allanore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avouac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="163" to="168" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Knock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Terenghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Bunker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Bull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Dowd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Polak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="73" to="78" />
			<date type="published" when="1993">2010. 1993</date>
		</imprint>
	</monogr>
	<note>Clin Rheumatol</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Digital ulcers in systemic sclerosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Korn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Matucci</forename><surname>Cerinic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3985" to="3993" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Bosentan treatment of digital ulcers related to systemic sclerosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Matucci-Cerinic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="32" to="38" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gatfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mueller Grandjean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clozel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Nayler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">e47662</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension</title>
		<author>
			<persName><forename type="first">M</forename><surname>Iglarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Landskroner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Pharmacol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="457" to="467" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Preliminary criteria for the classification of systemic sclerosis (scleroderma)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Rodnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="581" to="590" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Scleroderma (systemic sclerosis): classification, subsets and pathogenesis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Leroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmajer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="202" to="205" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tracey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="878" to="882" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Steen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1984" to="1991" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation</title>
		<author>
			<persName><forename type="first">B</forename><surname>Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Fries</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="167" to="178" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">21. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hilbe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Methods Med Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="219" to="242" />
			<date type="published" when="2007">2011. 2007</date>
			<publisher>Cambridge University Press</publisher>
		</imprint>
	</monogr>
	<note>Negative Binomial Regression</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension</title>
		<author>
			<persName><forename type="first">T</forename><surname>Pulido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Adzerikho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Channick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="809" to="818" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Macitentan for the treatment of idiopathic pulmonary fibrosis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Raghu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Million-Rousseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Morganti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1622" to="1632" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the treatment of systemic sclerosis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Kowal-Bielecka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avouac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="620" to="628" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Tingey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smuczek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pope</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis</title>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1460" to="1471" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Hachulla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Hatron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Carpentier</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-207001</idno>
		<idno>doi:10</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<date type="published" when="1136">2015. 1136 /annrheumdis-2014-207001</date>
		</imprint>
	</monogr>
	<note>published online May</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Krieg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guillevin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="718" to="721" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">participating members of the Schleroderma Clinical Trials Consortium</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pope</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Treatment of systemic sclerosis complications: what to use when first-line treatment fails</title>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="42" to="55" />
			<date type="published" when="2012">2012</date>
		</imprint>
		<respStmt>
			<orgName>Canadian Scleroderma Research Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Morelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ferri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Polettini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="255" to="260" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Significance of plasma endothelin-1 levels in patients with systemic sclerosis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Yamane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Suzuki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1566" to="1571" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Circulating endothelin-1 levels in systemic sclerosis subsets</title>
		<author>
			<persName><forename type="first">R</forename><surname>Vancheeswaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Magoulas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Efrat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1838" to="1844" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist</title>
		<author>
			<persName><forename type="first">M</forename><surname>Iglarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Binkert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="736" to="745" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
